Ebola virus disease (EVD) is a severe infectious disease caused by the Ebola virus, classified by the World Health Organization as a high-risk infectious disease. Since its first outbreak in Africa in 1976, this virus has caused several public health crises that have garnered global attention. Its high transmissibility and mortality rate have made it a focus of long-term monitoring and research in the international medical community.
This article will provide a detailed analysis of the transmission routes, clinical manifestations, diagnostic methods, and prevention strategies of the Ebola virus. Understanding this key information can help the public recognize risks and take appropriate measures during an outbreak. The overview of the Ebola virus covers basic knowledge to the latest prevention and treatment measures, providing a comprehensive knowledge framework.
The virus primarily spreads through direct contact with the bodily fluids of infected individuals. Initial symptoms are similar to those of general influenza but may rapidly progress to multi-organ failure. Currently, there is no specific antiviral treatment, but timely supportive therapy can improve survival rates. The following sections will explain the key features and response strategies of this disease in stages.
The Ebola virus belongs to the Filoviridae family, with viral particles shaped like long filaments. The original host of the virus is fruit bats, which transmit the virus to humans through animal hosts, and then it spreads through human contact. Once the virus enters the human body through damaged skin or mucous membranes, it rapidly replicates and destroys the immune system, leading to coagulopathy and tissue damage.
High-risk contact situations include:
The incubation period typically ranges from 2 to 21 days, with an average of 8 to 10 days. Initial symptoms include fever, headache, muscle pain, and fatigue; these nonspecific symptoms can easily be confused with other febrile illnesses. Subsequently, the following may appear:
Viral load correlates positively with the severity of symptoms, and some patients may only present with mild symptoms. Bleeding tendencies are a late-stage feature, including gum bleeding, vomiting blood, or blood in stools, at which point mortality rates significantly increase. Children and the elderly may deteriorate more rapidly and require special attention.
Clinical diagnosis requires a combination of epidemiological history and laboratory tests. Initial symptoms are similar to those of malaria or Marburg virus disease, so specialized tests are necessary:
The diagnostic process includes three stages: first, assessing contact history and symptoms; second, collecting serum and bodily fluid specimens; and finally, confirming the viral gene sequence in a specialized laboratory. Diagnostic results must be reported to health authorities within 24 hours to initiate epidemic response mechanisms. Contacts of suspected cases must undergo 21 days of monitoring.
Currently, there are no targeted antiviral drugs that can completely cure Ebola virus infection. Treatment primarily consists of supportive therapy:
Recent treatment advancements include vaccination and immunotherapy. The rVSV-ZEBOV vaccine has shown over 80% efficacy in contacts and is recommended for high-risk groups during the early stages of an outbreak. Experimental plasma therapy utilizes antibodies from recovered patients to neutralize the virus, but strict control of transfusion compatibility and infection risks is necessary.
Preventive measures are divided into personal protection and public health strategies. At the individual level, it is necessary to:
Key community measures include:
If you have traveled to an outbreak area or had contact with suspected cases and develop fever, unexplained bleeding, or diarrhea, you should immediately seek medical attention in an isolation ward. The infectious period is within 14 days of symptom onset, during which strict protection is required when contacting others. Medical institutions must initiate infection control procedures within 2 hours upon receiving a suspected case.
High-risk groups (such as healthcare workers and animal researchers) should undergo regular health screenings. If any of the following signs appear: persistent abdominal pain, unexplained vomiting of blood, multiple bruises, immediate reporting to health authorities and arranging for isolation diagnosis is necessary. Returnees from outbreak areas, even without symptoms, are advised to undergo 14 days of health monitoring.
Early symptoms of Ebola virus disease, such as fever, headache, and muscle pain, may resemble those of influenza or a common cold. However, Ebola is often accompanied by severe gastrointestinal symptoms (such as diarrhea and vomiting) and bleeding tendencies (such as gum bleeding or skin bruising). If you have recently been in contact with an outbreak area or confirmed cases, you should seek medical attention immediately and disclose your travel history.
What clinically validated treatment methods are currently available?As of 2023, antiviral drugs such as Remdesivir and monoclonal antibody combinations (such as REGN-EB3, mAb114) have been proven to reduce mortality rates and should be used early in symptom onset. Supportive treatment (fluid replacement, maintaining blood pressure and organ function) remains critical, while experimental plasma therapy should be evaluated on a case-by-case basis.
What is the quarantine observation period after contact with an Ebola patient?Contacts must undergo 21 days of medical monitoring (the longest viral incubation period), with daily monitoring of temperature and symptoms. If symptoms such as fever appear, immediate isolation and initiation of infection control measures are required. Those without symptoms should still be monitored for health status after the quarantine period ends.
Can the Ebola virus be transmitted through the air? How should one protect themselves correctly?The Ebola virus primarily spreads through direct contact with the bodily fluids of infected individuals, and there is currently no evidence to suggest it spreads through the air. Proper protection requires wearing protective clothing, gloves, and masks, and strict handwashing after contact. Healthcare workers handling suspected cases should use personal protective equipment (PPE) and follow no-touch operating procedures.
What Ebola vaccines are currently certified for use? How effective are they?The "Ervebo" vaccine (rVSV-ZEBOV) has received emergency use authorization from the World Health Organization, providing protection within 10 days of vaccination, with clinical trials showing an efficacy of up to 97.5% in preventing infection. Another vaccine, "Imojev," is suitable for emergency vaccination of contacts, and both must be stored and transported under cold chain conditions.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
